Eprodisate
Identification
- Generic Name
- Eprodisate
- DrugBank Accession Number
- DB06405
- Background
Eprodisate slows the decline of renal function in AA amyloidosis.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 204.21
Monoisotopic: 203.976230326 - Chemical Formula
- C3H8O6S2
- Synonyms
- 1,3-propanedisulfonic acid
- Eprodisate
- Propane-1,3-disulfonate
- Propane-1,3-disulfonic acid
- Propane-1,3-disulphonate
- External IDs
- NC-503
Pharmacology
- Indication
Investigated for use/treatment in amyloidosis.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Decline in renal function associated with Amyloid A (AA) amyloidosis can be slowed by eprodisate (Kiacta), a drug that inhibits the deposit of the complex protein in tissues. AA amyloidosis is a serious, frequently fatal disorder involving deposits of amyloid fibrils in various organs and tissues. It is a complication of many chronic inflammatory disorders, but little is known about its etiology or natural history. Eprodisate delays the progression of AA amyloidosis-associated renal disease.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Kiacta
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 6QFP76V7S7
- CAS number
- 21668-77-9
- InChI Key
- MGNVWUDMMXZUDI-UHFFFAOYSA-N
- InChI
- InChI=1S/C3H8O6S2/c4-10(5,6)2-1-3-11(7,8)9/h1-3H2,(H,4,5,6)(H,7,8,9)
- IUPAC Name
- propane-1,3-disulfonic acid
- SMILES
- OS(=O)(=O)CCCS(O)(=O)=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 379112
- ChEMBL
- CHEMBL2111092
- ZINC
- ZINC000005225211
- Wikipedia
- 1,3-Propanedisulfonic_acid
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Prevention Amyloidosis 1 2 Completed Treatment Syndrome, Metabolic / Type 2 Diabetes Mellitus 1 2, 3 Completed Treatment Familial Mediterranean Fever (FMF ) / Gastrointestinal Diseases / Kidney Diseases / Nephrotic Syndrome / Rheumatoid Arthritis / Secondary (AA) Amyloidosis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 14.2 mg/mL ALOGPS logP -2.6 ALOGPS logP -1.7 Chemaxon logS -1.2 ALOGPS pKa (Strongest Acidic) -2 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 108.74 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 36.21 m3·mol-1 Chemaxon Polarizability 16.64 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0udi-0290000000-a881bdcaa79204d74055 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0udi-0090000000-347f0598ed48c2aac773 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-00ec-8910000000-b3e6eb27ed3827404088 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0udi-3090000000-02ec8c685655f0c9eb36 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-001i-9200000000-1802d1893372ec917e13 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-9000000000-a9072c477dd6ccde98e2 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 142.8268418 predictedDarkChem Lite v0.1.0
Drug created at March 19, 2008 16:29 / Updated at February 21, 2021 18:52